USANA Health Sciences (NYSE:USNA) Price Target Lowered to $35.00 at DA Davidson

USANA Health Sciences (NYSE:USNA) had its price target trimmed by DA Davidson from $38.00 to $35.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock.

Separately, StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Price Performance

NYSE USNA opened at $36.58 on Wednesday. The business’s 50-day simple moving average is $37.98 and its 200-day simple moving average is $42.55. The firm has a market capitalization of $696.89 million, a P/E ratio of 11.40, a P/E/G ratio of 1.20 and a beta of 0.89. USANA Health Sciences has a 1-year low of $34.15 and a 1-year high of $55.45.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The company had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same period in the previous year, the firm earned $0.59 earnings per share. On average, equities research analysts expect that USANA Health Sciences will post 2.5 EPS for the current fiscal year.

Insider Transactions at USANA Health Sciences

In related news, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now directly owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now directly owns 2,503 shares of the company’s stock, valued at $111,208.29. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 7,940 shares of company stock valued at $311,670. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in USNA. BOKF NA raised its stake in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after buying an additional 494 shares in the last quarter. DGS Capital Management LLC lifted its holdings in USANA Health Sciences by 61.8% during the 1st quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock worth $352,000 after buying an additional 2,773 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of USANA Health Sciences in the 2nd quarter worth approximately $340,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of USANA Health Sciences by 4.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after acquiring an additional 322 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.